We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit
EUCRU

Delisted

EUCRU was delisted on the 26th of April, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of EUCRU yet.

EUCRU Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q2 2023, worth a combined $0 — down 100% from $6.72M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EUCRU and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Verition Fund Management, exiting entirely with an estimated $4.12M sold.

  • 0 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q2 2023, down from 4 in Q1 2023.
  • Funds reported $0 of Eucrates Biomedical Acquisition Corp. Unit stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q2 2023 and 4 closed out, a net change of -4 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q2 2023 was Verition Fund Management, an estimated $4.12M sold.

Based on aggregated 13F filings for Q2 2023.